Treated for newly diagnosed Hodgkin 's lymphoma with brentuximab vedotin: one case report and literature review
10.3760/cma.j.issn.1008-6706.2017.23.020
- VernacularTitle:布妥昔单抗治疗CD30阳性霍奇金淋巴瘤一例并文献复习
- Author:
Tao MA
1
;
Kaifeng YUAN
;
Hongyun XING
;
Xiaoming LI
;
Pengqiang WU
;
Yan CHEN
;
Pan LI
Author Information
1. 西南医科大学附属医院血液内科
- Keywords:
Lymphoma;
Antigens,CD30;
Brentuximab vedotin;
Prognosis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(23):3598-3600
- CountryChina
- Language:Chinese
-
Abstract:
Objective To deepen the understanding of curative effect and adverse drug reaction of brentuximab vedotin in the treatment of Hodgkin's lymphoma.Methods One case of newly diagnosed Hodgkin's lymphoma who treated with brentuximab vedotin was collected.The clinical features,laboratory examination,treatment procedure,prognosis were analyzed,and the relevant literature was reviewed.Results The patient was twenty years old,female,found the right neck masses for five days,diagnosed with Hodgkin's lymphoma,mixed cell type,stage Ⅳ group B.Chose the chemotherapy regimen BV + GABVD for 4 courses,the PET-CT indicated CR,then used GABVD 4 courses,now in the stage of clinical observation and followed up.Conclusion BV is a kind of antibody-drug conjugate which targeted on CD30 protein.The FDA approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.The common adverse reactions are granulocyte,peripheral neuropathy,fatigue,nausea and vomiting.BV can significantly improve the prognosis of CD30 positive Hodgkin's lymphoma,but need to pay attention to the prevention of adverse reactions.
